Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines

Cancer Clinical Trial

Official title:

Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02159482
• Other study ID #: Pro00014489
• Status: Terminated
• Phase: Phase 2
• First received: June 6, 2014
• Last updated: July 21, 2014
• Start date: November 2005
• Est. completion date: May 2008

Study information

• Verified date: June 2014
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This research study is for people who have previously received cancer vaccines. The investigators are testing a form of therapy known as interferon alfa-2a, which is commercially available as the drug Roferon®-A, to see if it can be used to help boost the effects of the cancer vaccine and help the immune system attack the cancer.

It is believed that the body's immune system can attack tumor cells and kill them. This is thought to be due to immune cells called T cells which can recognize special proteins on the surface of tumors as a signal to fight the cancer. However, the vaccine may not work very well if the protein signal is too weak for the T cells to find your tumors. The investigators think that interferon alfa-2a can signal the cancer cells in the body to make more proteins that may allow the T cells to recognize and kill the cancer cells better.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: May 2008
• Est. primary completion date: May 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must have received a cancer vaccine targeting tumor antigen.

• 6 months following the last dose of the prior vaccine.

• Measurable disease defined by the RECIST criteria (lesions that can be accurately measured in at least one dimension with the longest diameter = 20 mm using conventional techniques or = 10 mm with spiral CT.)

• Karnofsky performance status greater than or equal to 70%

• Estimated life expectancy > 6 months.

• Age = 18 years.

• Adequate, hematologic function with:

• WBC = 3000 mm3

• hemoglobin = 9 mg/dL (may transfuse or use erythropoietin to achieve this level)

• platelets = 100,000/mm3

• Adequate, renal and hepatic function with:

• serum creatinine < 2.5 mg/dL

• bilirubin < 2.0 mg/dL

• SGOT/SGPT < 1.5 x upper limit of normal

• No prior grade 3 or 4 major organ or allergic toxicity attributable to the prior vaccine

• Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.

• Ability to return to Duke University Medical Center for adequate follow-up, as required by this protocol.

Exclusion Criteria:

• Patients with concurrent chemotherapy, radiation therapy, or immunotherapy should be excluded. Patients may not have received interferon previously.

• Patients with either previously irradiated or new CNS (central nervous system) metastases at entry are excluded. Pre-enrollment head CT is not required if not indicated by clinical signs or symptoms.

• Patients with a history of auto-immune disease, such as but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis.

• Patients with serious intercurrent chronic or acute illness, such as cardiac disease, (NYHA class III or IV), hepatic disease, or other illness considered by the PI as unwarranted high risk for investigational drug treatment.

• Patients with a medical or psychological impediment to probable compliance with the protocol.

• Concurrent second malignancy other than non-melanoma skin cancer, or controlled superficial bladder cancer.

• Presence of an active acute or chronic infection including: an urinary tract infection, HIV (as determined by ELISA and confirmed by Western Blot) or viral hepatitis (as determined by HBsAg and Hepatitis C serology). HIV patients are excluded based on immuno-suppression, which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections.

• Patients on steroid therapy (or other immuno-suppressives, such as azathioprine or cyclosporin A) are excluded on the basis of potential immune suppression. Patients must have had 6 weeks of discontinuation of any steroid therapy (except that used as pre-medication for chemotherapy or contrast-enhanced studies) prior to enrollment.

• Patients with egg allergies or allergies to any component of the vaccine should be excluded from the protocol.

• Pregnant and nursing women should be excluded from the protocol since this research may have unknown and harmful effects on an unborn child or on young children. If the patient is sexually active, the patient must agree to use a medically acceptable form of birth control in order to be in this study. It is not known whether the treatment used in this study could affect the sperm and could potentially harm a child that maybe fathered while on this study.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cancer

Intervention

Drug:
• Interferon Alfa-2a

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Duke University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Clinical Responders (Complete Response + Partial Response)	Response determination will be made according to the RECIST criteria. Complete response defined as the disappearance of target lesion, confirmed at 1-4 weeks. Partial response defined as 30% decrease in longest dimension of target lesion, confirmed at 1-4 weeks.	4 weeks	No
Secondary	Proportion of Patients Experiencing an Increase in the Magnitude of the Tumor Antigen-specific Immune Response	The proportion of patients experiencing an increase in the magnitude of the tumor antigen-specific immune response following the administration of interferon will also be estimated. Immune response will be determined by ELISPOT analysis.	4 weeks	No